Literature DB >> 6293978

Ceftriaxone: in vitro activity against 410 bacterial isolates compared with cefotaxime.

A Digranes, E Benonisen, W L Dibb.   

Abstract

The in vitro activity of the two new cephalosporins, cefotaxime and ceftriaxone, against 410 bacterial isolates was compared using an agar dilution method. Both compounds were highly active against Enterobacteriaceae, including indole-positive Proteus and Providencia; the great majority of the isolates were inhibited by 0.06 mg/l of either drug. Activity against Pseudomonas aeruginosa and Staphylococcus aureus was moderate, and enterococci were resistant. All Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae isolates were susceptible to 0.03 mg/l of either drug. The isolates belonging to the Bacteroides fragilis group were inhibited over a wide range of concentrations and some were highly resistant (MIC greater than or equal to 64 mg/l). There were no significant differences in the antibacterial activity of the two drugs against our isolates. Both drugs may be of potential use in the treatment of serious infections caused by Enterobacteriaceae; they may prove to be a useful alternative to the aminoglycosides.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6293978     DOI: 10.1007/bf01640881

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  17 in total

1.  Antibiotic sensitivity testing. Report of an international collaborative study.

Authors:  H M Ericsson; J C Sherris
Journal:  Acta Pathol Microbiol Scand B Microbiol Immunol       Date:  1971

2.  Rapid identification of prompt lactose-fermenting genera within the familyh Enterobacteriaceae.

Authors:  O Closs; A Digranes
Journal:  Acta Pathol Microbiol Scand B Microbiol Immunol       Date:  1971

3.  Moxalactam.

Authors: 
Journal:  Lancet       Date:  1981-07-04       Impact factor: 79.321

4.  In vitro susceptibility of Haemophilus influenzae and neisseria gonorrhoeae to Ro 13-9904 in comparison with other beta-lactam antibiotics.

Authors:  W S Ng; P Y Chau; K Arnold
Journal:  Antimicrob Agents Chemother       Date:  1981-05       Impact factor: 5.191

5.  Antibacterial activity of cefotaxime and other newer cephalosporins (in vitro and in vivo).

Authors:  E Schrinner; M Limbert; L Penasse; A Lutz
Journal:  J Antimicrob Chemother       Date:  1980-09       Impact factor: 5.790

6.  The in vitro activity of netilmicin against 357 clinical isolates of Enterobacteriaceae, Pseudomonas aeruginosa and Staphylococcus aureus.

Authors:  A Digranes; W L Dibb; B Ostervold
Journal:  Scand J Infect Dis Suppl       Date:  1980

7.  Pharmacokinetics of Ro 13-9904, a broad-spectrum cephalosporin.

Authors:  M Seddon; R Wise; A P Gillett; R Livingston
Journal:  Antimicrob Agents Chemother       Date:  1980-08       Impact factor: 5.191

8.  Ro 13-9904, a long-acting broad-spectrum cephalosporin: in vitro and in vivo studies.

Authors:  P Angehrn; P J Probst; R Reiner; R L Then
Journal:  Antimicrob Agents Chemother       Date:  1980-12       Impact factor: 5.191

9.  Activities of new beta-lactam antibiotics against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.

Authors:  A S Prince; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1981-10       Impact factor: 5.191

10.  In vitro antibacterial activity and susceptibility of the cephalosporin Ro 13-9904 to beta-lactamases.

Authors:  K Shannon; A King; C Warren; I Phillips
Journal:  Antimicrob Agents Chemother       Date:  1980-08       Impact factor: 5.191

View more
  1 in total

Review 1.  Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  D M Richards; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.